<p>Shum Financial Group Inc. 在第三季度购买了 AbbVie Inc. (NYSE:ABBV - 免费报告) 的新股份，根据该公司最近向证券交易委员会（SEC）披露的信息。该公司购买了 5,336 股该公司的股票，价值约为 1,235,000 美元。</p>
<ul>
<li>3 只分析师看好的股息增长股票，预计在 2026 年表现优异</li>
</ul>
<p>其他一些机构投资者和对冲基金最近也增加或减少了在 ABBV 的持股。挪威银行在第二季度收购了 AbbVie 的新股份，价值 42,882,000,000 美元。Laurel Wealth Advisors LLC 在第二季度将其在 AbbVie 的持股增加了 18,384.4%。Laurel Wealth Advisors LLC 目前拥有 5,705,964 股该公司的股票，价值 1,059,141,000 美元，在此期间又购买了 5,675,095 股。Assenagon Asset Management S.A. 在第二季度将其在 AbbVie 的持股增加了 550.9%。Assenagon Asset Management S.A. 目前拥有 4,332,054 股该公司的股票，价值 804,116,000 美元，在上个季度又购买了 3,666,521 股。先锋集团（Vanguard Group Inc.）在第二季度将其在 AbbVie 的持股增加了 1.9%。先锋集团目前拥有 177,298,707 股该公司的股票，价值 32,910,186,000 美元，在上个季度又购买了 3,380,842 股。最后，Kingstone Capital Partners Texas LLC 在第二季度购买了 AbbVie 的新股份，价值约 581,817,000 美元。机构投资者和对冲基金持有该公司 70.23% 的股份。</p>
<h2>分析师评级变动</h2>
<p>几位分析师最近对该股票发表了看法。摩根士丹利将 AbbVie 的股票目标价从 261.00 美元上调至 269.00 美元，并在 12 月 12 日的报告中给予该股票 &#34;超配&#34; 评级。瑞银集团将 AbbVie 的目标价从 195.00 美元上调至 220.00 美元，并在 11 月 7 日的研究报告中给予该股票 &#34;中性&#34; 评级。BMO Capital Markets 将 AbbVie 的目标价从 215.00 美元上调至 240.00 美元，并在 9 月 12 日的研究报告中给予该公司 &#34;跑赢大盘&#34; 评级。古根海姆将 AbbVie 的目标价从 227.00 美元上调至 242.00 美元，并在 10 月 20 日的报告中给予该股票 &#34;买入&#34; 评级。最后，华尔街 Zen 在 12 月 13 日的报告中将 AbbVie 的评级从 &#34;买入&#34; 上调至 &#34;强力买入&#34;。三位研究分析师给予该股票 &#34;强力买入&#34; 评级，十三位给予 &#34;买入&#34; 评级，八位给予 &#34;持有&#34; 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 &#34;适度买入&#34;，共识目标价为 245.84 美元。</p>
<ul>
<li>股息强劲：3 只为长期投资而生的蓝筹股</li>
</ul>
<p><strong>查看我们关于 AbbVie 的最新研究报告</strong></p>
<h2>AbbVie 股票表现</h2>
<p>AbbVie 股票在周四开盘价为 228.55 美元。该公司的市值为 4039.4 亿美元，市盈率为 173.14，市盈增长比率为 1.30，贝塔值为 0.36。该公司的债务与股本比率为 44.14，流动比率为 0.72，速动比率为 0.60。该业务的 50 日移动平均线为 226.67 美元，200 日移动平均线为 213.37 美元。AbbVie Inc. 的 12 个月低点为 164.39 美元，12 个月高点为 244.81 美元。</p>
<ul>
<li>HIMS 的股价波动不定。投资者应该入场吗？</li>
</ul>
<p>AbbVie (NYSE:ABBV - 获取免费报告) 最近在 10 月 31 日发布了季度财报。该公司报告每股收益 (EPS) 为 1.86 美元，超出分析师的共识预期 1.77 美元，超出 0.09 美元。AbbVie 的净利润率为 4.00%，股本回报率为 3,216.47%。该公司在本季度的收入为 157.8 亿美元，而分析师预期为 155.8 亿美元。在去年同期，该公司每股收益为 3.00 美元。该业务本季度的收入较去年同期增长了 9.1%。AbbVie 已将其 2025 年第四季度的指导目标设定为 3.320-3.360 EPS。作为一个整体，卖方分析师预测 AbbVie Inc. 今年将发布 12.31 的每股收益。</p>
<h2>AbbVie 增加股息</h2>
<p>该公司最近还宣布了一项季度股息，将于 2 月 17 日（星期二）支付。1 月 16 日（星期五）的股东将获得 1.73 美元的股息。该股息的除息日为 1 月 16 日（星期五）。这代表着 6.92 美元的年化股息，收益率为 3.0%。这比 AbbVie 之前的季度股息 1.64 美元有所增加。AbbVie 的股息支付比率为 496.97%。</p>
<h2>关于 AbbVie</h2>
<p>（免费报告）</p>
<p>AbbVie 是一家全球性的、以研究为驱动的生物制药公司，成立于 2013 年，作为雅培（Abbott Laboratories）的分拆公司，总部位于伊利诺伊州北芝加哥。该公司专注于发现、开发和商业化针对复杂且常常是慢性医疗条件的治疗方案。其业务涵盖研究与开发、制造、监管事务和商业化，重点是将专业药物推向多个治疗领域的市场。</p>
<p>AbbVie 的产品组合和研发管道涵盖多个主要治疗类别，包括免疫学、肿瘤学、神经科学、病毒学和女性健康。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票，胜过 AbbVie</li>
<li>这个假期你花的每一美元都值得</li>
<li>假期惊喜：1 美元让你拥有一切</li>
<li>美国 “最糟糕” 的圣诞促销</li>
<li>市场恐慌：特朗普刚刚对你的股票投下了炸弹</li>
<li>你家族的财富将在 2026 年到期？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UCNlN5bWJvbD1BQkJW?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UCNlN5bWJvbD1BQkJW"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 AbbVie 吗？</h2>
<p>在你考虑艾伯维之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而艾伯维并不在名单上。</p>
<p>虽然艾伯维目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

艾伯维

<p>Shum Financial Group Inc. 在第三季度收购了 AbbVie Inc.（纽约证券交易所代码：ABBV）约 124 万美元的新股份，购买了 5,336 股。其他机构投资者也增加了对 AbbVie 的持股，其中挪威银行和 Laurel Wealth Advisors 的投资尤为显著。分析师们提高了对 AbbVie 的目标价，普遍评级为 “适度买入”，目标价为 245.84 美元。AbbVie 最近报告了强劲的季度收益，并宣布将每股股息提高至 1.73 美元，反映出 3.0% 的收益率</p>

<p>Shum Financial Group Inc. purchased a new stake in AbbVie Inc. (NYSE:ABBV - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 5,336 shares of the company's stock, valued at approximately $1,235,000.</p>
<div class="lb-trans"><p>Shum Financial Group Inc. 在第三季度购买了 AbbVie Inc. (NYSE:ABBV - 免费报告) 的新股份，根据该公司最近向证券交易委员会（SEC）披露的信息。该公司购买了 5,336 股该公司的股票，价值约为 1,235,000 美元。</p>
</div><ul>
<li>3 Dividend Growth Stocks Analysts Are Upgrading for 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只分析师看好的股息增长股票，预计在 2026 年表现优异</li>
</ul>
</div><p>A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ABBV. Norges Bank acquired a new stake in shares of AbbVie in the 2nd quarter worth $4,288,200,000. Laurel Wealth Advisors LLC grew its holdings in shares of AbbVie by 18,384.4% in the second quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company's stock valued at $1,059,141,000 after purchasing an additional 5,675,095 shares during the period. Assenagon Asset Management S.A. increased its position in AbbVie by 550.9% during the second quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company's stock worth $804,116,000 after purchasing an additional 3,666,521 shares during the last quarter. Vanguard Group Inc. increased its position in AbbVie by 1.9% during the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company's stock worth $32,910,186,000 after purchasing an additional 3,380,842 shares during the last quarter. Finally, Kingstone Capital Partners Texas LLC purchased a new position in AbbVie during the second quarter worth about $581,817,000. Institutional investors and hedge funds own 70.23% of the company's stock.</p>
<div class="lb-trans"><p>其他一些机构投资者和对冲基金最近也增加或减少了在 ABBV 的持股。挪威银行在第二季度收购了 AbbVie 的新股份，价值 42,882,000,000 美元。Laurel Wealth Advisors LLC 在第二季度将其在 AbbVie 的持股增加了 18,384.4%。Laurel Wealth Advisors LLC 目前拥有 5,705,964 股该公司的股票，价值 1,059,141,000 美元，在此期间又购买了 5,675,095 股。Assenagon Asset Management S.A. 在第二季度将其在 AbbVie 的持股增加了 550.9%。Assenagon Asset Management S.A. 目前拥有 4,332,054 股该公司的股票，价值 804,116,000 美元，在上个季度又购买了 3,666,521 股。先锋集团（Vanguard Group Inc.）在第二季度将其在 AbbVie 的持股增加了 1.9%。先锋集团目前拥有 177,298,707 股该公司的股票，价值 32,910,186,000 美元，在上个季度又购买了 3,380,842 股。最后，Kingstone Capital Partners Texas LLC 在第二季度购买了 AbbVie 的新股份，价值约 581,817,000 美元。机构投资者和对冲基金持有该公司 70.23% 的股份。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several analysts have recently weighed in on the stock. Morgan Stanley raised their price target on shares of AbbVie from $261.00 to $269.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, December 12th. UBS Group raised their target price on AbbVie from $195.00 to $220.00 and gave the stock a &#34;neutral&#34; rating in a research note on Friday, November 7th. BMO Capital Markets upped their price target on AbbVie from $215.00 to $240.00 and gave the company an &#34;outperform&#34; rating in a research note on Friday, September 12th. Guggenheim increased their price target on AbbVie from $227.00 to $242.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, October 20th. Finally, Wall Street Zen upgraded shares of AbbVie from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a report on Saturday, December 13th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $245.84.</p>
<div class="lb-trans"><p>几位分析师最近对该股票发表了看法。摩根士丹利将 AbbVie 的股票目标价从 261.00 美元上调至 269.00 美元，并在 12 月 12 日的报告中给予该股票 &#34;超配&#34; 评级。瑞银集团将 AbbVie 的目标价从 195.00 美元上调至 220.00 美元，并在 11 月 7 日的研究报告中给予该股票 &#34;中性&#34; 评级。BMO Capital Markets 将 AbbVie 的目标价从 215.00 美元上调至 240.00 美元，并在 9 月 12 日的研究报告中给予该公司 &#34;跑赢大盘&#34; 评级。古根海姆将 AbbVie 的目标价从 227.00 美元上调至 242.00 美元，并在 10 月 20 日的报告中给予该股票 &#34;买入&#34; 评级。最后，华尔街 Zen 在 12 月 13 日的报告中将 AbbVie 的评级从 &#34;买入&#34; 上调至 &#34;强力买入&#34;。三位研究分析师给予该股票 &#34;强力买入&#34; 评级，十三位给予 &#34;买入&#34; 评级，八位给予 &#34;持有&#34; 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 &#34;适度买入&#34;，共识目标价为 245.84 美元。</p>
</div><ul>
<li>Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul</li>
</ul>
<div class="lb-trans"><ul>
<li>股息强劲：3 只为长期投资而生的蓝筹股</li>
</ul>
</div><p><strong>Check Out Our Latest Research Report on AbbVie</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 AbbVie 的最新研究报告</strong></p>
</div><h2>AbbVie Stock Performance</h2>
<div class="lb-trans"><h2>AbbVie 股票表现</h2>
</div><p>Shares of AbbVie stock opened at $228.55 on Thursday. The stock has a market capitalization of $403.94 billion, a price-to-earnings ratio of 173.14, a price-to-earnings-growth ratio of 1.30 and a beta of 0.36. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.72 and a quick ratio of 0.60. The business has a 50-day moving average of $226.67 and a 200 day moving average of $213.37. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81.</p>
<div class="lb-trans"><p>AbbVie 股票在周四开盘价为 228.55 美元。该公司的市值为 4039.4 亿美元，市盈率为 173.14，市盈增长比率为 1.30，贝塔值为 0.36。该公司的债务与股本比率为 44.14，流动比率为 0.72，速动比率为 0.60。该业务的 50 日移动平均线为 226.67 美元，200 日移动平均线为 213.37 美元。AbbVie Inc. 的 12 个月低点为 164.39 美元，12 个月高点为 244.81 美元。</p>
</div><ul>
<li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li>
</ul>
<div class="lb-trans"><ul>
<li>HIMS 的股价波动不定。投资者应该入场吗？</li>
</ul>
</div><p>AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same period in the prior year, the firm earned $3.00 earnings per share. The business's revenue for the quarter was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, sell-side analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.</p>
<div class="lb-trans"><p>AbbVie (NYSE:ABBV - 获取免费报告) 最近在 10 月 31 日发布了季度财报。该公司报告每股收益 (EPS) 为 1.86 美元，超出分析师的共识预期 1.77 美元，超出 0.09 美元。AbbVie 的净利润率为 4.00%，股本回报率为 3,216.47%。该公司在本季度的收入为 157.8 亿美元，而分析师预期为 155.8 亿美元。在去年同期，该公司每股收益为 3.00 美元。该业务本季度的收入较去年同期增长了 9.1%。AbbVie 已将其 2025 年第四季度的指导目标设定为 3.320-3.360 EPS。作为一个整体，卖方分析师预测 AbbVie Inc. 今年将发布 12.31 的每股收益。</p>
</div><h2>AbbVie Increases Dividend</h2>
<div class="lb-trans"><h2>AbbVie 增加股息</h2>
</div><p>The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a $1.73 dividend. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.0%. This is a boost from AbbVie's previous quarterly dividend of $1.64. AbbVie's dividend payout ratio is 496.97%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度股息，将于 2 月 17 日（星期二）支付。1 月 16 日（星期五）的股东将获得 1.73 美元的股息。该股息的除息日为 1 月 16 日（星期五）。这代表着 6.92 美元的年化股息，收益率为 3.0%。这比 AbbVie 之前的季度股息 1.64 美元有所增加。AbbVie 的股息支付比率为 496.97%。</p>
</div><h2>About AbbVie</h2>
<div class="lb-trans"><h2>关于 AbbVie</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.</p>
<div class="lb-trans"><p>AbbVie 是一家全球性的、以研究为驱动的生物制药公司，成立于 2013 年，作为雅培（Abbott Laboratories）的分拆公司，总部位于伊利诺伊州北芝加哥。该公司专注于发现、开发和商业化针对复杂且常常是慢性医疗条件的治疗方案。其业务涵盖研究与开发、制造、监管事务和商业化，重点是将专业药物推向多个治疗领域的市场。</p>
</div><p>AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.</p>
<div class="lb-trans"><p>AbbVie 的产品组合和研发管道涵盖多个主要治疗类别，包括免疫学、肿瘤学、神经科学、病毒学和女性健康。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than AbbVie</li>
<li>The Best $1 You'll Spend This Holiday Season</li>
<li>Holiday surprise: $1 gets you everything</li>
<li>America’s “most deplorable” Christmas sale</li>
<li>Market Panic: Trump Just Dropped a Bomb on Your Stocks</li>
<li>Your family's wealth expires in 2026?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 AbbVie</li>
<li>这个假期你花的每一美元都值得</li>
<li>假期惊喜：1 美元让你拥有一切</li>
<li>美国 “最糟糕” 的圣诞促销</li>
<li>市场恐慌：特朗普刚刚对你的股票投下了炸弹</li>
<li>你家族的财富将在 2026 年到期？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABBV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in AbbVie Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 AbbVie 吗？</h2>
</div><p>Before you consider AbbVie, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑艾伯维之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而艾伯维并不在名单上。</p>
</div><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然艾伯维目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Shum Financial Group Inc. 在艾伯维公司建立了价值 124 万美元的头寸